Skip to content

Effect of Epidural Hydromorphone Combined With Ropivacaine in Labor Analgesia

Effect of Epidural Hydromorphone Combined With Ropivacaine in Labor Analgesia

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05901441
Enrollment
240
Registered
2023-06-13
Start date
2022-06-01
Completion date
2023-05-30
Last updated
2023-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Labor Pain

Brief summary

The purpose of this study is to compare the effects of three different doses of hydromorphone combined with ropivacaine and sufentanil combined with ropivacaine in epidural labor analgesia through prospective clinical trials, so as to explore whether hydromorphone combined with ropivacaine has advantages in epidural labor analgesia, and find out the optimal dose of hydromorphone. Participants will be randomly allocated to four groups: H1 group,H2 group,H3 group and SF group.For those in H1 group: they will be administered with15 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in H3 group: they will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in SF group: they will be administered with 40 ug/ml sufentanil and 0.08% ropivacaine for epidural labor analgesia. The goal of this clinical trial is to provide a new treatment option for pregnant women in epidural labor analgesia, and to provide a basis for hydromorphone combined with ropivacaine in epidural labor analgesia.

Interventions

DRUGHydromorphone

For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone

DRUGSufentanil

For those in SF group: they will be administered with 40 ug/ml sufentanil

DRUGRopivacaine

0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms

Sponsors

Maternal and Child Health Hospital of Hubei Province
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

no contraindication of intraspinal anesthesia the American Society of Anesthesiologists(ASA) physical status ranked Ⅰ-Ⅱ competent to provide informed consent

Exclusion criteria

poor respiratory functions severe cardiovascular diseases

Design outcomes

Primary

MeasureTime frameDescription
Visual Analogue Scale(VAS)30 minutes-1 hourVAS will be monitored and recorded at 6 time points, including the time of entering the operating room(Time 0), when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), when the first dose is given for 30 minutes(Time 3), 30 minutes after delivery (Time 4), and 60 minutes after delivery (Time 5). The VAS consists of a 10 cm line,with two end points representing 0 (no pain) and 10 (pain as bad as it could possibly be).

Secondary

MeasureTime frameDescription
Mean arterial pressure(MAP)30 minutes-1.5 hoursMAP will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
Pulse oxygen saturation30 minutes-1.5 hoursPulse oxygen saturation will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
Duration of analgesia30 minutes-1.5 hoursDefined as the time from labor analgesia to delivery of the fetus.
Heart rate(HR)30 minutes-1.5 hoursHR will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
Adverse reactions30 minutes-1.5 hoursThe occurrence of adverse reactions(nausea, vomiting, skin itching and other adverse reactions).
The Apgar scores30 minutes-1.5 hoursThe Apgar scores of 1 and 5 minutes after birth will be recorded.
The number of compressions30 minutes-1.5 hoursThe number of compressions by electronic analgesia pump from labor analgesia to delivery of the fetus.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026